Crinetics Pharmaceuticals (CRNX) Non-Current Deffered Revenue (2017 - 2026)

Crinetics Pharmaceuticals' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 22.42% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 22.42% YoY), while the FY2025 annual figure was $3.8 million, down 19.01% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $3.3 million, down from $3.8 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $7.2 million in Q1 2022, with the low at $3.3 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $4.8 million (2023), against an average of $5.1 million.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue surged 94928.57% in 2022, then fell 26.36% in 2023.
• Crinetics Pharmaceuticals' Non-Current Deffered Revenue stood at $6.1 million in 2022, then declined by 22.14% to $4.8 million in 2023, then dropped by 0.97% to $4.7 million in 2024, then declined by 19.01% to $3.8 million in 2025, then decreased by 12.18% to $3.3 million in 2026.
• Business Quant data shows CRNX's Non-Current Deffered Revenue at $3.3 million in Q1 2026, $3.8 million in Q4 2025, and $4.1 million in Q3 2025.